CONDITION
Epilepsy in Dogs
Epilepsy describes a pattern of recurring seizures — moments when electrical activity in the brain becomes suddenly disordered, producing visible changes in movement, awareness, or behaviour. In many dogs, no underlying cause can be identified through testing; in others, seizures arise from structural brain changes, metabolic disturbances, or exposure to certain substances. Owners most often arrive on this page after witnessing a first seizure or after a pattern has emerged. What was observed may range from brief, subtle episodes — a vacant stare, rhythmic facial twitching — to full-body convulsions lasting one or two minutes. The experience tends to be distressing to witness, and questions commonly centre on what caused the event, whether it will recur, and what can be done. This page explores the observable signs that accompany seizure activity, the investigative steps used to understand what may be driving the pattern, and the medical approaches that exist to reduce seizure frequency or severity over time. The course and outlook vary widely between individuals.
Why this matters now
Epilepsy in dogs tends to appear in two broad windows. Idiopathic epilepsy—seizures without an identifiable structural brain abnormality—most often begins between one and five years of age, with certain breeds including Border Collies, Labrador Retrievers, German Shepherds, and Belgian Shepherds showing higher prevalence. Seizures that begin outside this window, particularly in older dogs, may signal acquired causes such as brain tumours, inflammatory disease, or metabolic disturbance.
The pattern of seizures can vary widely between individuals. Some dogs experience isolated events separated by months or years, whilst others develop clusters—multiple seizures within a short period—or a gradual increase in frequency over time. The interval between seizures, their duration, and the character of each event often shift as the condition evolves, which is why tracking patterns over months tends to be more informative than interpreting a single episode.
Signals & patterns
Early signals
Brief loss of awareness
The dog may pause mid-activity, stare blankly, or seem unresponsive for seconds to a minute. These episodes can be subtle and are sometimes mistaken for distraction or fatigue, particularly if they occur infrequently.
Repetitive facial movements
Chewing motions, lip-smacking, or repeated swallowing without food present can occur during a focal seizure. The dog may appear conscious but disconnected, and the behaviour typically resolves on its own within a minute or two.
Single limb twitching or stiffness
One leg may jerk rhythmically, or the dog may hold a limb awkwardly whilst remaining otherwise alert. This localised activity can precede more generalised seizures or remain isolated over time.
Unusual restlessness beforehand
In the minutes or hours before a seizure, some dogs show changes in behaviour—pacing, seeking attention, hiding, or appearing anxious. This prodromal phase is not present in every dog, but when it occurs it can become a recognisable pattern.
Later signals
Generalised collapse with paddling
The dog loses consciousness, falls onto one side, and paddles the limbs rhythmically. This tonic-clonic seizure is the most widely recognised form and typically lasts one to two minutes, though the recovery period—confusion, disorientation, pacing—may extend for minutes to hours.
Clusters within a day
Multiple seizures occurring within a 24-hour window, often separated by partial recovery, can develop in dogs whose epilepsy is progressing or poorly controlled. The pattern may emerge gradually or appear suddenly after a period of relative stability.
Prolonged post-seizure confusion
After a seizure, the dog may wander aimlessly, fail to recognise familiar people or places, or appear temporarily blind. This post-ictal phase can lengthen over time in some individuals, particularly when seizures become more frequent or severe.
Click to read about the biological mechanisms
How this is usually investigated
Investigation begins with detailed seizure history—frequency, duration, appearance, and any observed triggers or patterns—alongside a thorough physical and neurological examination. Initial blood and urine tests help identify or exclude metabolic causes such as hypoglycaemia, hepatic dysfunction, or electrolyte disturbances that can provoke reactive seizures. Advanced imaging of the brain may be considered when seizure characteristics, age of onset, or examination findings suggest structural disease, though many cases of idiopathic epilepsy show no visible abnormalities on imaging.
Chemistry panel
Complete blood count
Bile acid stimulation test
Magnetic resonance imaging (MRI)
Cerebrospinal fluid analysis
Options & trade-offs
Management typically combines anti-seizure medication with attention to environmental factors and seizure documentation. No single approach eliminates all seizures in every dog, and finding a workable balance between seizure control and quality of life often involves adjustments over time. Different families find different combinations practical, and what constitutes acceptable control varies with individual circumstances and the dog's response to treatment.
Phenobarbital therapy
Phenobarbital enhances GABA-mediated inhibition in the brain and has been used for decades as a foundation of canine epilepsy management. It is given twice daily, with doses adjusted based on blood level monitoring and seizure control. Many dogs achieve meaningful reduction in seizure frequency, though complete freedom from seizures is not always attained.
Trade-offs: Common effects include increased thirst, appetite, and urination, particularly in the first weeks, and some dogs show sedation or mild incoordination during dose adjustments. Long-term use requires periodic blood monitoring to assess liver enzyme induction and ensure levels remain within the therapeutic range.
Potassium bromide therapy
Potassium bromide acts by competing with chloride at neuronal receptors, raising the threshold for seizure activity. It can be used alone or in combination with phenobarbital, and is given once or twice daily. Without a loading-dose protocol, it takes approximately three to four months to reach steady-state concentrations in the bloodstream; loading-dose protocols can achieve therapeutic levels within days but require close veterinary oversight.
Trade-offs: The long half-life means that adjustments to maintenance dosing take months to fully manifest in seizure control. Gastrointestinal upset can occur, particularly if doses are not given with food, and some dogs develop a characteristic stiff-legged gait (bromism) at higher blood levels.
Levetiracetam therapy
Levetiracetam modulates neurotransmitter release through synaptic vesicle protein interactions and is often added when other medications provide incomplete control. It is given two or three times daily and reaches therapeutic levels within hours to days, allowing relatively rapid assessment of effect.
Trade-offs: The short half-life means missed doses can lead to breakthrough seizures, and the frequency of administration may be less practical for some households. It tends to produce fewer sedative effects than phenobarbital, though response varies and not all dogs show additional benefit when it is introduced.
Seizure diary and trigger management
Systematic recording of seizure date, time, duration, and context can reveal patterns or precipitating factors such as stress, sleep disruption, or dietary changes. Some owners identify individual triggers that, when modified, appear to reduce seizure frequency, though this is not universal.
Trade-offs: Requires consistent record-keeping and may not reveal clear patterns in all cases. Environmental modification can complement medication but rarely replaces it, and apparent triggers may reflect correlation rather than causation.
Dietary modification
Medium-chain triglyceride-enriched diets have been explored for their potential to alter brain metabolism and raise seizure threshold, drawing on principles observed in ketogenic diets used in human epilepsy. Some dogs show a reduction in seizure frequency when transitioned to these formulations, though the degree of benefit varies widely.
Trade-offs: Evidence in dogs remains limited compared to pharmaceutical interventions, and not all individuals respond. Dietary changes are typically considered as an adjunct to medication rather than a replacement, and palatability or gastrointestinal tolerance may vary.
Common misconceptions
"A dog having a seizure is in pain and needs to be physically restrained or comforted during the event."
Seizures involve involuntary neuronal activity, and the dog is typically unconscious or unaware during generalised convulsions. Physical restraint can lead to injury for both dog and owner, and the most useful action is to ensure the animal cannot fall or strike objects, then allow the event to run its course in a safe space.
"Anti-seizure medication will stop all seizures completely."
The objective of medication is typically to reduce seizure frequency and severity to a level that maintains quality of life, rather than to eliminate seizures entirely. Many dogs continue to have occasional seizures despite treatment, and the definition of successful control varies between individuals and their circumstances.
"Once started, anti-seizure medication must be continued for life without any possibility of adjustment or withdrawal."
While many dogs remain on medication long-term, doses can often be adjusted as patterns change, and in some cases withdrawal may be considered after extended seizure-free periods, particularly in reactive epilepsy where the underlying cause has resolved. Any change in medication requires gradual adjustment under veterinary guidance, as abrupt withdrawal can precipitate cluster seizures or status epilepticus.
Related conditions
Canine Cognitive Dysfunction
Canine cognitive dysfunction can present with behavioural changes that may include altered awareness or episodes of staring, which owners occasionally describe in ways that overlap with the presentation of focal seizures. Both conditions reflect underlying neurological change in older dogs, though the mechanisms and patterns differ.
Hypothyroidism in Dogs
Hypothyroidism has historically been discussed as a potential contributor to seizure activity in some dogs, though the relationship remains uncertain and seizures attributed to low thyroid function are uncommon. Thyroid testing may form part of the initial investigation when seizures first appear.
Degenerative Myelopathy in Dogs
Degenerative myelopathy involves progressive spinal cord degeneration and typically presents with hindlimb weakness rather than seizures, but both conditions reflect primary neurological disease. Distinguishing between weakness from spinal disease and post-seizure weakness can be relevant in dogs with gait changes.
Intervertebral Disc Disease in Dogs
Intervertebral disc disease causing spinal cord compression can occasionally produce episodes of pain-related vocalisation or collapse that owners may interpret as seizure-like events. Both conditions involve the nervous system but affect different anatomical regions and produce distinct patterns on examination.
Addisons Disease in Dogs
Addison's disease can cause episodic weakness or collapse during adrenal crises, which may sometimes be confused with seizure activity, particularly when episodes involve altered consciousness. Both conditions involve recurrent episodes and can require long-term monitoring, though the underlying mechanisms are metabolic rather than neurological in Addison's.
Epilepsy management tends to evolve over months and years as seizure patterns declare themselves and response to treatment becomes clearer. Tracking how individual episodes cluster, whether they follow particular life events, and how medication side effects balance against seizure control can all inform ongoing conversations about adjustment. Related neurological and behavioural patterns—such as changes in sleep, appetite, or temperament between seizures—may also form part of a broader picture worth observing over time.
Last reviewed: 24 April 2026 · Dr Alastair Greenway MRCVS